bioAffinity, AvMEDICAL Announce CyPath Lung Distribution Agreement

bioAffinity Technologies and AvMEDICAL have announced a distribution agreement for the CyPath Lung test in the U.S. government healthcare market. Medical Product Outsourcing reported the announcement and identified AvMEDICAL as the distribution partner for CyPath Lung in the stated market.

Distribution agreement covers CyPath Lung

According to Medical Product Outsourcing, the agreement brings together bioAffinity Technologies and AvMEDICAL around distribution of the CyPath Lung test. The publisher described the market scope as U.S. government healthcare.

The announcement identifies the product, the companies involved and the targeted healthcare market. Medical Product Outsourcing characterizes the arrangement as a distribution agreement for CyPath Lung rather than providing further terms of the agreement.

Commercial focus for healthcare technology professionals

For medical sales professionals following healthcare technology distribution activity, the announcement places focus on CyPath Lung and the U.S. government healthcare market. AvMEDICAL is named as the distribution partner in Medical Product Outsourcing’s report.

The agreement is also relevant to stakeholders tracking how diagnostic testing products are aligned with defined customer channels. The reported scope is limited to the U.S. government healthcare market, with CyPath Lung as the test covered by the arrangement.

Key points from the announcement

• bioAffinity Technologies and AvMEDICAL announced a distribution agreement.
• The agreement concerns the CyPath Lung test.
• The stated market is U.S. government healthcare.
• Medical Product Outsourcing reported the announcement.

Medical Product Outsourcing did not provide additional agreement details in the supplied report. The announcement nonetheless marks a distribution-commercial development involving bioAffinity Technologies, AvMEDICAL and CyPath Lung within the stated healthcare market.